NetworkNewsBreaks – Nkarta, Inc. (NASDAQ: NKTX) Featured in Mizuho Securities Research Report
Nkarta, Inc. (NASDAQ: NKTX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning, Nkarta press released IND clearance for its off-the-shelf CD19 CAR-NK product candidate NKX019 in relapsed/refractory B-cell malignancies. The company expects to dose the first patient in 2H21 (in line with previous language). All good here, continuing with the mantra that is a co-lead program at Nkarta along w/ NKX101.” To request access to the full report, visit http://nnw.fm/SaZ9d About Nkarta, Inc. Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (“NK”) cell…







